101 related articles for article (PubMed ID: 12415827)
1. A new class of anti-cancer drugs: HDAC-inhibitors.
Pelicci PG
Suppl Tumori; 2002; 1(4):S66. PubMed ID: 12415827
[No Abstract] [Full Text] [Related]
2. The novel histone deacetylase inhibitor NVP-LAQ824: an addition to the therapeutic armamentarium in leukemia?
Grant S
Leukemia; 2004 Dec; 18(12):1931-3. PubMed ID: 15496978
[No Abstract] [Full Text] [Related]
3. New agents for acute myelogenous leukemia.
Zwiebel JA
Leukemia; 2000 Mar; 14(3):488-90. PubMed ID: 10720147
[TBL] [Abstract][Full Text] [Related]
4. Histone deacetylase inhibitors: latest developments, trends and prospects.
Moradei O; Maroun CR; Paquin I; Vaisburg A
Curr Med Chem Anticancer Agents; 2005 Sep; 5(5):529-60. PubMed ID: 16178777
[TBL] [Abstract][Full Text] [Related]
5. [Histone deacetylase inhibitors--new anticancer agents?].
Yoshida M; Horinouchi S
Tanpakushitsu Kakusan Koso; 2000 Apr; 45(6 Suppl):1090-5. PubMed ID: 10771678
[No Abstract] [Full Text] [Related]
6. Targeting aberrant transcriptional repression in acute myeloid leukemia.
Moe-Behrens GH; Pandolfi PP
Rev Clin Exp Hematol; 2003 Jun; 7(2):139-59. PubMed ID: 14763160
[TBL] [Abstract][Full Text] [Related]
7. Assays for the identification and evaluation of histone acetyltransferase inhibitors.
Wynne Aherne G; Rowlands MG; Stimson L; Workman P
Methods; 2002 Mar; 26(3):245-53. PubMed ID: 12054880
[TBL] [Abstract][Full Text] [Related]
8. HDAC inhibitors for the treatment of cancer.
Secrist JP; Zhou X; Richon VM
Curr Opin Investig Drugs; 2003 Dec; 4(12):1422-7. PubMed ID: 14763127
[TBL] [Abstract][Full Text] [Related]
9. Novel agents in acute myeloid leukemia.
Aribi A; Ravandi F; Giles F
Cancer J; 2006; 12(2):77-91. PubMed ID: 16630396
[TBL] [Abstract][Full Text] [Related]
10. N-hydroxy-3-phenyl-2-propenamides as novel inhibitors of human histone deacetylase with in vivo antitumor activity: discovery of (2E)-N-hydroxy-3-[4-[[(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2-propenamide (NVP-LAQ824).
Remiszewski SW; Sambucetti LC; Bair KW; Bontempo J; Cesarz D; Chandramouli N; Chen R; Cheung M; Cornell-Kennon S; Dean K; Diamantidis G; France D; Green MA; Howell KL; Kashi R; Kwon P; Lassota P; Martin MS; Mou Y; Perez LB; Sharma S; Smith T; Sorensen E; Taplin F; Trogani N; Versace R; Walker H; Weltchek-Engler S; Wood A; Wu A; Atadja P
J Med Chem; 2003 Oct; 46(21):4609-24. PubMed ID: 14521422
[TBL] [Abstract][Full Text] [Related]
11. Acetylation of proteins as novel target for antitumor therapy: review article.
Di Gennaro E; Bruzzese F; Caraglia M; Abruzzese A; Budillon A
Amino Acids; 2004 Jul; 26(4):435-41. PubMed ID: 15290351
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of histone deacetylase activity increases chromosomal instability by the aberrant regulation of mitotic checkpoint activation.
Shin HJ; Baek KH; Jeon AH; Kim SJ; Jang KL; Sung YC; Kim CM; Lee CW
Oncogene; 2003 Jun; 22(25):3853-8. PubMed ID: 12813458
[TBL] [Abstract][Full Text] [Related]
13. Development of histone deacetylase inhibitors for cancer treatment.
Marchion D; Münster P
Expert Rev Anticancer Ther; 2007 Apr; 7(4):583-98. PubMed ID: 17428177
[TBL] [Abstract][Full Text] [Related]
14. Clinical potential of histone deacetylase inhibitors as stand alone therapeutics and in combination with other chemotherapeutics or radiotherapy for cancer.
Karagiannis TC; El-Osta A
Epigenetics; 2006; 1(3):121-6. PubMed ID: 17965606
[TBL] [Abstract][Full Text] [Related]
15. Histone deacetylases in acute myeloid leukaemia show a distinctive pattern of expression that changes selectively in response to deacetylase inhibitors.
Bradbury CA; Khanim FL; Hayden R; Bunce CM; White DA; Drayson MT; Craddock C; Turner BM
Leukemia; 2005 Oct; 19(10):1751-9. PubMed ID: 16121216
[TBL] [Abstract][Full Text] [Related]
16. Molecular therapeutic approaches to acute myeloid leukemia: targeting aberrant chromatin dynamics and signal transduction.
Piazza F; Semenzato G
Expert Rev Anticancer Ther; 2004 Jun; 4(3):387-400. PubMed ID: 15161438
[TBL] [Abstract][Full Text] [Related]
17. Histone deacetylase: a target for antiproliferative and antiprotozoal agents.
Meinke PT; Liberator P
Curr Med Chem; 2001 Feb; 8(2):211-35. PubMed ID: 11172676
[TBL] [Abstract][Full Text] [Related]
18. The potential of histone deacetylase inhibitors in lung cancer.
Aparicio A
Clin Lung Cancer; 2006 Mar; 7(5):309-12. PubMed ID: 16640801
[TBL] [Abstract][Full Text] [Related]
19. HATs off to Hop: recruitment of a class I histone deacetylase incriminates a novel transcriptional pathway that opposes cardiac hypertrophy.
Hamamori Y; Schneider MD
J Clin Invest; 2003 Sep; 112(6):824-6. PubMed ID: 12975465
[TBL] [Abstract][Full Text] [Related]
20. Histone deacetylase inhibitors and demethylating agents: clinical development of histone deacetylase inhibitors for cancer therapy.
Piekarz RL; Sackett DL; Bates SE
Cancer J; 2007; 13(1):30-9. PubMed ID: 17464244
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
